Does Connecticut HUSKY Cover Wegovy or Zepbound? Forms, Tests and the 2025 Law Change

No. As of November 2026, Connecticut’s HUSKY Health program has no prior authorization route for Wegovy, Zepbound or another GLP-1 prescribed for weight loss alone; the only forms the state posts are for heart-risk reduction, the liver disease MASH, sleep apnea and type 2 diabetes.^[5][1][2][3] A 2023 law had required obesity-drug coverage for members with a BMI over 35, but the 2025 budget act removed that requirement and made such coverage optional.^[7]

Does HUSKY cover Wegovy or Zepbound for weight loss?

Not through any published route. The heart-risk and sleep apnea forms say the drug is not covered when the request fails their tests, and the diabetes form requires a type 2 diabetes diagnosis code on every new prescription.^[1][3][4] The department’s notice to members who are turned down at the pharmacy says the same thing in plain terms: the medication needs a diagnosis code showing type 2 diabetes.^[6] Federal law gives states the option to leave weight-loss drugs out of Medicaid.^[9] Connecticut’s state plan, in an amendment federal regulators approved effective June 1, 2025, covers only two weight-loss drugs: orlistat and phentermine, with brand-name Xenical in place of orlistat depending on net cost or availability.^[15]

What happened to Connecticut's law on obesity drugs?

It was rewritten. Section 17b-278l, passed in 2023 and effective July 1 of that year, directed the commissioner to cover FDA-approved obesity drugs for Medicaid and HUSKY B members with a BMI above 35.^[7] The 2025 budget act, effective July 1, 2025, deleted that mandate. The statute now describes the coverage as optional, says the department provides it only once a state plan amendment is approved, and narrows the drugs it covers to obesity drugs for people with type 2 diabetes and drugs for a related condition in people with obesity, after prior authorization and step therapy.^[7]

The rewritten law also caps any required step therapy at 180 days, waives it when BMI is 40 or higher and a provider certifies that surgery under anesthesia is scheduled within six months, and asks the commissioner to report GLP-1 use and costs to the legislature every year from January 15, 2026.^[7] Another 2025 addition told the department to petition the federal government about lower-cost generic GLP-1s.^[7] As of November 6, 2026, the department’s pharmacy page listed no GLP-1 form for obesity without one of the conditions below.^[5]

When will HUSKY approve Wegovy or Zepbound?

Each of the three non-diabetes uses on these drugs’ labels has its own form.^[10][11] Every one of those forms is limited to adults 18 and older, and each also asks for a treatment plan with active diet, activity or behavioral changes.^[1][2][3]

Two details matter most. First, the heart and sleep apnea forms exclude people with diabetes, who are sent to the diabetes GLP-1s instead.^[1][3] Second, the MASH form asks for a liver biopsy result, since it requires histologic documentation along with the fibrosis stage and activity score.^[2] Our guides to Zepbound for sleep apnea and GLP-1s and MASH explain the evidence behind those uses.

Does HUSKY cover Ozempic and Mounjaro for diabetes?

Yes. The diabetes form dated July 1, 2026 lists Mounjaro, the Ozempic pen, Trulicity, Victoza and Byetta as preferred, each needing a diagnosis code. Ozempic tablets, Rybelsus, generic liraglutide and generic exenatide are non-preferred.^[4] A non-preferred drug needs a 30-day trial and failure of one preferred GLP-1, or a documented reason that none can be used, and stomach side effects alone do not count as intolerance unless the prescriber justifies stopping.^[4]

What if a request does not fit the form?

Connecticut prints a fallback on the forms themselves. When a request fails the criteria, each of the three forms says a Letter of Medical Necessity must be reviewed, emailed to rx.lmn@ct.gov, and points to the state’s definition of medical necessity.^[1][2][3] That definition covers services needed to treat or ameliorate a medical condition that are consistent with accepted medical standards and no more costly than an equally effective alternative.^[8] A strong letter cites the person’s own diagnoses, the treatments already tried and published evidence. It is a review, not a promise of approval.

How do you appeal a HUSKY denial?

• Requests. Prescribers fax the form to 1-866-759-4110; the pharmacy prior authorization line is 1-866-409-8386.^[1]
• Hearings. A member can ask in writing for a hearing by writing to the department’s hearings office (OLCRAH) at 55 Farmington Avenue, Hartford, CT 06105-3725, or by fax to (860) 424-5729. Questions about hearings go to 1-800-462-0134.^[6]
• Deadline. Use the date on your denial notice. The department’s GLP-1 notice gives no day count, so file soon.^[6]

A hearing has the most to work with when the dispute is over a covered use, such as whether a sleep study or PAP record was enough. Our walkthrough of prior authorization and appeals covers what to send, and the state Medicaid GLP-1 checker compares Connecticut with other states.

What about children and teens on HUSKY?

Wegovy’s label includes obesity treatment from age 12, but all three HUSKY forms are for adults.^[10][1] Federal law requires Medicaid to provide necessary treatment found through child health screening for people under 21, even when the state plan does not cover it.^[12] We found no Connecticut document that applies that rule to GLP-1s. A family can use the Letter of Medical Necessity route and ask for review under EPSDT, the federal child-health benefit, by name.

What are the options without coverage?

For weight loss alone, the drugs in HUSKY’s state plan are orlistat and phentermine, so ask the prescriber whether either fits.^[15] For Wegovy or Zepbound, paying cash is the main route. Lilly’s savings card for insured patients excludes Medicaid enrollees.^[13] Self-pay prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time for Lilly’s Zepbound.^[13][14] Check each offer’s terms on government-program enrollment first. Our list of the cheapest GLP-1 routes without insurance compares them, and the Connecticut page lists sellers that ship to the state.